Newsletter

Biotech Stocks

If you wondered why share prices fall after a capital raising, Botanix is the ‘perfect’ poster child

We thought this was a perfect time to ponder the question,' Why share prices fall after a capital raising', in light of what happened with Botanix Pharmaceuticals (ASX:BOT). Its shares fell 33% in less than an hour of trading. Now, shouldn't investors be happy that the company has $45m more cash? Let's just say that…

ByNick SundichFebruary 18, 2026

Rhythm Biosciences (ASX:RHY): Since picking up Genetype, it has never looked back and is more than a one-trick pony!

Investors may remember Rhythm Biosciences (ASX:RHY) for its ColoSTAT test, but it is Genetype that is arguably more exciting. The company now has a substantially larger market awaiting us, and while its commercialisation strategy for ColoSTAT has changed, this strategy has been successful. Wait, has Rhythm received TGA approval? Yes and no - it's a long…

ByNick SundichFebruary 17, 2026

Here are some ASX stocks that will benefit from a higher AUD, and stocks that will lose

The Aussie dollar has been surging in recent weeks and there are ASX stocks that will benefit from a higher AUD - as well as some that will lose. We cannot be certain how much longer this run will go on for, but we do know it is on a run right now. After several quarters…

ByNick SundichFebruary 16, 2026

CSL CEO Paul McKenzie has departed, now what for the fallen biotech giant?

In a bombshell 4pm announcement, investors learned that CSL CEO Paul McKenzie was departing the company effective that very afternoon following a tenure of nearly 3 years. It was clear that something had to give, but this is still a shock as it occurred a day before company results and resulted in McKenzies' tenure lasting…

ByNick SundichFebruary 11, 2026

This company just made an IND submission to the US FDA, here’s why its a big step!

Imagion Biosystems (ASX:IBX) just made a IND submission. This is a big deal for the company, and we thought it would be the perfect time to explain to investors just what this means. What are the Best ASX Stocks to invest in right now? Check our buy/sell tips [sg_popup id="23914" event="click"] [/sg_popup] Here's what you need to know about…

ByNick SundichFebruary 10, 2026

PYC Therapeutics (ASX:PYC): Its been raising ~$650m to fund 4 clinical assets for multiple years!

PYC Therapeutics (ASX:PYC) is currently in the Top 25 ASX healthcare stocks and is the 4th largest biotech, only trailing Telix, Mesoblast and Neuren. Clearly this is one worth looking into and this was before a capital raising that would be $650m and purportedly fund the company into next decade. What are the Best ASX Life…

ByNick SundichFebruary 5, 2026

Epiminder (ASX:EPI): Less than 2 months since its IPO, this medtech made its first implant

Epiminder (ASX:EPI) only listed on the ASX at the end of November last year, but just announced to market that it completed the first implant of its Minder system in the USA. The company's Minder system is an epilepsy monitoring technology which is in a global clinical trial which will enrol over 200 patients. Shares only…

ByNick SundichJanuary 21, 2026

Neuren Pharmaceuticals (ASX:NEU) Surges 6% on US$700m DAYBUE Target: Time to Buy?

DAYBUE royalties could climb fast if US targets land Neuren Pharmaceuticals (ASX: NEU) jumped 6% on Wednesday after its US partner, Acadia Pharmaceuticals, shared big news at the J.P. Morgan Healthcare Conference. Acadia now expects DAYBUE sales to hit US$700 million by 2028, sending Neuren shares to around A$20.47. The stock has climbed more than…

ByUjjwal MaheshwariJanuary 15, 2026

NeuroScientific (ASX:NSB) Reports 75% Response Rate in Crohn’s Trial: Is This Stem Cell Stock a Buy?

NeuroScientific jumps on early Crohn’s stem cell results NeuroScientific Biopharmaceuticals (ASX: NSB) surged 43% on Tuesday after announcing promising early results from its stem cell program. Three out of four patients achieved a clinical response in a Special Access Program for fistulising Crohn's disease. The company's StemSmart therapy showed a 75% success rate in treating one…

ByUjjwal MaheshwariJanuary 14, 2026

Island Pharmaceuticals (ASX:ILA) Surges 12% on US Patent Win: Speculative Buy or Too Risky?

Island Pharmaceuticals Secures US Patent for Galidesivir Island Pharmaceuticals (ASX: ILA) jumped 12 per cent this week after announcing it secured a US patent for galidesivir, its antiviral drug designed to fight some of the world's deadliest viruses. While a broad US patent protects galidesivir’s use in COVID-19 until July 2042, the company just secured…

ByUjjwal MaheshwariJanuary 8, 2026

the Kick-ass Multipurpose WordPress Theme

Biotech Stocks

If you wondered why share prices fall after a capital raising, Botanix is the ‘perfect’ poster child

Rhythm Biosciences (ASX:RHY): Since picking up Genetype, it has never looked back and is more than a one-trick pony!

Here are some ASX stocks that will benefit from a higher AUD, and stocks that will lose

CSL CEO Paul McKenzie has departed, now what for the fallen biotech giant?

This company just made an IND submission to the US FDA, here’s why its a big step!

PYC Therapeutics (ASX:PYC): Its been raising ~$650m to fund 4 clinical assets for multiple years!

Epiminder (ASX:EPI): Less than 2 months since its IPO, this medtech made its first implant

Neuren Pharmaceuticals (ASX:NEU) Surges 6% on US$700m DAYBUE Target: Time to Buy?

NeuroScientific (ASX:NSB) Reports 75% Response Rate in Crohn’s Trial: Is This Stem Cell Stock a Buy?

Island Pharmaceuticals (ASX:ILA) Surges 12% on US Patent Win: Speculative Buy or Too Risky?

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Biotech Stocks

Stocks in Spotlight

Add Your Heading Text Here